Loading...
Loading...
COGT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.9M |
| Gross Profit | -0.9M |
| Operating Expense | 59.6M |
| Operating I/L | -59.6M |
| Other Income/Expense | 4.2M |
| Interest Income | 4.2M |
| Pretax | -55.4M |
| Income Tax Expense | -0.9M |
| Net Income/Loss | -55.4M |
Cogent Biosciences, Inc. is a biotechnology company specializing in precision therapies for genetically defined diseases. Its lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation in systemic mastocytosis and other mutations in KIT exon 17 found in advanced gastrointestinal stromal tumors. The company also holds a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib, further expanding its therapeutic portfolio.
